Sugi Predict

Sugi Predict / Compounds / SCHEMBL8577

SCHEMBL8577

SCHEMBL8577

Nc1ncnc2c1ncn2Cc1oc2ccccc2c(=O)c1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 4/20 0.53
▸ PI4KA P42356 3/20 0.53
▸ PI4K2B Q8TCG2 3/20 0.53
▸ PI4K2A Q9BTU6 3/20 0.53
▸ PI4KB Q9UBF8 3/20 0.53
▸ PIK3CD O00329 7/20 0.46
▸ EGFR P00533 4/20 0.46
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ PIK3R1 P27986 2/20 0.44
▸ ERBB2 P04626 1/20 0.42
▸ BRAF P15056 1/20 0.42
▸ KDR P35968 1/20 0.42
▸ TEK Q02763 1/20 0.42
▸ AURKB Q96GD4 1/20 0.42
▸ PIK3CB P42338 1/20 0.42
▸ PIK3CG P48736 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29651680 1.00 ADORA2A (0.53) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL8166 0.93 ADORA2A (0.47) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL30670890 0.93 ADORA2A (0.47) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL11901826 0.92 ADORA2A (0.57) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL8903 0.90 ADORA2A (0.49) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL30013159 0.90 ADORA2A (0.49) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL15688607 0.90 ADORA2A (0.55) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL8426 0.90 PIK3CD (0.46) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL30013691 0.90 PIK3CD (0.46) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL7930 0.89 ADORA2A (0.48) ADORA2API4KAPI4K2BPI4K2API4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US claimed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US claimed
EP-4292596-A1 METHOD AND COMBINATION FOR TREATING TUMORS Curon Biopharmaceutical (Shanghai) Co., Limited (CN) 2023-12-20 — — EP claimed
CN-117222413-A Methods and combinations for treating tumors 同润生物医药(上海)有限公司 2023-12-12 — — CN claimed
WO-2022171121-A1 METHOD AND COMBINATION FOR TREATING TUMORS 同润生物医药(上海)有限公司 2022-08-18 — — WO claimed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US claimed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 — — EP claimed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 — — EP claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US claimed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) 2024-05-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ADORA2A 1556/4885PI4KA 98/4885PI4K2B 82/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ADORA2A 1556/4885PI4KA 98/4885PI4K2B 82/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ADORA2A 1556/4885PI4KA 98/4885PI4K2B 82/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A ADORA2A 1129/4885PI4KA 156/4885PI4K2B 140/4885
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS PDCD1, PDCD1LG2, CD274 ADORA2A 2412/4885PI4KA 58/4885PI4K2B 90/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ADORA2A 1556/4885PI4KA 98/4885PI4K2B 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.